Venker Eric 4

What Happened
Eric Venker, President of Roivant Sciences and CEO of Immunovant, exercised vested stock options and sold the resulting shares on April 20, 2026. He exercised options to acquire 200,000 shares at $3.85 per share (cost $770,000) and then sold 200,000 shares in an open-market transaction at a weighted-average price of $29.59 per share, generating approximately $5,918,000. The filing also shows a related derivative conversion line (200,000 shares at $0.00), reflecting the option exercise mechanics reported on the Form 4.

Key Details

• Transaction date: April 20, 2026; Form 4 filed April 22, 2026 (timely filing).
• Exercise: 200,000 shares exercised at $3.85 each — total exercise cost $770,000. (Footnote F2: options were fully vested.)
• Sale: 200,000 shares sold, weighted-average sale price $29.59, total proceeds ~$5,918,000. (Footnote F1: sales occurred at prices ranging $29.33–$29.88; weighted average reported.)
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Codes: M = option exercise/conversion; S = open-market sale.
• No 10b5-1 plan, gift, or tax-withholding details disclosed in the excerpt.

Context
This was an option exercise followed by an immediate sale of the acquired shares — a common liquidity move for insiders exercising vested options. The filing is factual and does not imply motive; purchases usually signal stronger bullish conviction, while exercises-then-sales often reflect routine liquidity or tax planning.